By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
DailynewsegyptDailynewsegypt
  • Home
  • Business
    BusinessShow More
    Japan's Nikkei ends higher, gains capped amid continued concerns over global financial crisis
    Japan’s Nikkei ends higher, gains capped amid continued concerns over global financial crisis
    March 27, 2023
    European Commission VP visits Egypt to discuss education, mobility, and migration issues
    European Commission VP visits Egypt to discuss education, mobility, and migration issues
    March 27, 2023
    Developers have to offer innovative products, state should provide more facilities to stimulate industry: Kareem Mamoun
    Developers have to offer innovative products, state should provide more facilities to stimulate industry: Kareem Mamoun
    March 27, 2023
    Tabarak Holding launches 4 exhibitions in Gulf region for Egyptian property export
    Tabarak Holding launches 4 exhibitions in Gulf region for Egyptian property export
    March 27, 2023
    Eight Developments, Gaballah Group sign contract with Mission 235 for Revolve Mall management
    Eight Developments, Gaballah Group sign contract with Mission 235 for Revolve Mall management
    March 27, 2023
  • Politics
    PoliticsShow More
    Germany has delivered Leopard 2 tanks to Ukraine: Scholz
    Ukraine gets first batch of Leopard 2 tanks from Germany
    March 28, 2023
    China’s president Xi met with the King of Saudi Arabia Salman bin Abdulaziz Al-Saud in 2017. Reuters/Alamy
    China’s latest diplomatic move will extend its trade, energy, financial and maritime power
    March 27, 2023
    Saudi Arabia, to the surprise of many, chose China to broker its deal with Iran in March 2023. Chinese Foreign Ministry/Anadolu Agency via Getty Image
    As longterm partnership with US fades, Saudi Arabia seeks to diversify its diplomacy – and recent deals with China, Iran and Russia fit this strategy
    March 27, 2023
    Mass Israel protests after Netanyahu fires defence minister
    Israeli PM calls for calm amid turmoil over government’s judicial overhaul
    March 27, 2023
    Somalia says army kills over 3,000 Al-Shabab militants in 6 months
    Somalia says army kills over 3,000 Al-Shabab militants in 6 months
    March 27, 2023
  • Interviews
    InterviewsShow More
    Developers have to offer innovative products, state should provide more facilities to stimulate industry: Kareem Mamoun
    Developers have to offer innovative products, state should provide more facilities to stimulate industry: Kareem Mamoun
    March 27, 2023
    Government should help Egyptian arts revive its pioneering role: Omar Abdel Aziz
    Government should help Egyptian arts revive its pioneering role: Omar Abdel Aziz
    March 15, 2023
    Interconnected healthcare systems in Africa require political will from North African leaders: Amref official
    Interconnected healthcare systems in Africa require political will from North African leaders: Amref official
    March 12, 2023
    EGX ready for government’s IPOs programme: Chairperson
    EGX ready for government’s IPOs programme: Chairperson
    February 15, 2023
    British International Investment invests $4.5bn in 700 businesses across Africa: Sherine Shohdy
    February 15, 2023
  • Culture
  • Opinion
  • Sports
  • Lifestyle
Reading: Novartis reveals new hope with overall survival benefit for HR+/HER2- advanced breast cancer patients
Share
Notification
Latest News
Germany has delivered Leopard 2 tanks to Ukraine: Scholz
Ukraine gets first batch of Leopard 2 tanks from Germany
Politics
China’s president Xi met with the King of Saudi Arabia Salman bin Abdulaziz Al-Saud in 2017. Reuters/Alamy
China’s latest diplomatic move will extend its trade, energy, financial and maritime power
Opinion Politics World
Saudi Arabia, to the surprise of many, chose China to broker its deal with Iran in March 2023. Chinese Foreign Ministry/Anadolu Agency via Getty Image
As longterm partnership with US fades, Saudi Arabia seeks to diversify its diplomacy – and recent deals with China, Iran and Russia fit this strategy
Opinion Politics
Japan's Nikkei ends higher, gains capped amid continued concerns over global financial crisis
Japan’s Nikkei ends higher, gains capped amid continued concerns over global financial crisis
Stock Market
Mass Israel protests after Netanyahu fires defence minister
Israeli PM calls for calm amid turmoil over government’s judicial overhaul
Politics
Aa
Aa
DailynewsegyptDailynewsegypt
  • Home
  • Business
  • Politics
  • Interviews
  • Culture
  • Opinion
  • Sports
  • Lifestyle
  • Home
  • Business
  • Politics
  • Interviews
  • Culture
  • Opinion
  • Sports
  • Lifestyle
Have an existing account? Sign In
Follow US
  • Advertise
© 2023 DNE News. All Rights Reserved.
Dailynewsegypt > Blog > Business > Novartis reveals new hope with overall survival benefit for HR+/HER2- advanced breast cancer patients
Business

Novartis reveals new hope with overall survival benefit for HR+/HER2- advanced breast cancer patients

Daily News Egypt
Last updated: 2021/12/01 at 11:19 PM
By Daily News Egypt 7 Min Read
Share
SHARE

Novartis Pharma SAE (Novartis Egypt) has announced final overall survival (OS) results for the Phase III MONALEESA-2 study. The study evaluated ribociclib in combination with letrozole compared to a placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease.

“Breast cancer is the most common form of cancer among Egyptian women affecting up to 34%. Approximately 15 – 20% of these breast cancers are diagnosed at the metastatic stage. Metastatic breast (stage IV) cancer is a breast cancer that has spread beyond the breast to other parts of the body, such as the lungs, liver, bones, or brain,” said Dr. Alaa Kandil, Professor of Clinical Oncology, Faculty of Medicine, Alexandria University.

“Overall survival is the ultimate goal that patients and oncologists seek in the treatment of advanced breast cancer. The overall survival (OS) rate is the length of time patients live after they are first diagnosed or begin treatment. It is a measure used to determine the effectiveness of new medications or therapeutic approaches. Today we discuss the overall survival results with ribociclib from the Phase III MONALEESA-2 study after a median follow-up of over six and a half years, the longest for any CDK4/6 inhibitor trial to date. This data is expected to change the way we practice medicine in advanced breast cancer,” added Dr. Kandil.

“The final analysis of the MONALEESA-2 trial evaluating ribociclib in combination with letrozole in the first line setting showed that after five years, the postmenopausal women with HR+/HER2- advanced breast cancer treated had more than a 50% chance of survival. This remarkable ribociclib overall survival data is highly encouraging and represents the longest reported median survival from a randomized trial in HR+/HER2- advanced breast cancer,” Dr Hamdy Abdel Azim, Professor of Clinical Oncology, Faculty of Medicine, Cairo University, said.

“In addition to that, a 12-month delay ‘in time to chemotherapy’ was observed with ribociclib (median 50.6 vs. 38.9 months) compared to those taking letrozole alone. This life extension, while also maintaining a good quality of life, is great news for our patients and is the building block for further progress,” Dr. Abdel Azim added.

In MONALEESA-2, the primary endpoint progression-free survival (PFS) was met at the initial analysis where ribociclib significantly improved progression free survival by 44%.

“The MONALEESA program continues to transform advanced breast cancer treatment, demonstrating remarkable consistency in terms of results, with three different phase III studies showing a significant improvement in overall survival for advanced hormonal breast cancer patients, regardless of the patients’ menopausal status, the extent of their metastases or whether it was a first or second line of therapy,2,5,” Dr Ahmed Hassan, Assistant Professor of Clinical Oncology, Faculty of Medicine, Ain Shams University and Member of the Women’s Health Outreach Program (WHOP), said. 

“Under the umbrella of the Egyptian Presidential Women’s Health Initiative, the Ministry of Health has introduced new treatment protocols for advanced breast cancer, making the best-in-class and most innovative medications available throughout Egypt. This is a transformative milestone in the treatment of advanced breast cancer – especially over the past two years – and an old dream that has come true,” Dr. Hassan added, “the Ministry of Health is paying increased attention to women with advanced breast cancer with the priority of minimizing the numbers of advanced breast cancer patients and providing all the support possible in terms of detection, examination, and treatment. This is even more applicable following the introduction of innovative targeted therapies, which offer patients new hope,” he added.

“The ultimate objective for all types of advanced cancer treatments is to slow down disease progression and help manage the disease effectively, while enabling patients to enjoy their regular lives for the longest time possible. In recent years, we have seen significant advancements in the management and treatment of breast cancer. There is a focus on targeted therapies that better meet the unique needs of patients with different types of breast cancer, and improve their life expectancy,” Dr. Heba El Zawahry, Professor of Medical Oncology, National Cancer Institute, Cairo University, said.

“When treatment offers long overall survival—and in this case, the longest ever reported in HR+/HER2- advanced breast cancer—patients have more time to be with their families and loved ones and, to pursue whatever makes them happy. This treatment gives them real hope while allowing them to maintain a good quality of life instead of obliging them to endure the intolerable sufferings of chemotherapy,” Dr. Heba El Zawahry added.

“Our mission is to improve and extend the lives of those with cancer and reimagine a world where advanced breast cancer becomes a manageable disease. As we reimagine medicine and strive for cure, our MONALEESA program continues to push boundaries by demonstrating that ribociclib is unique in its ability to give people living with advanced breast cancer more time,” Dr Sherif Amin, General Manager of Oncology at Novartis Pharma (Egypt, Morocco and Tunisia), said.

“For people with advanced hormonal breast cancer, these data are not just numbers, they mean additional life milestones. However, we will not rest as we continue to investigate the full potential of ribociclib to patients. Our commitment to collaborating with the Ministry of Health under the umbrella of the presidential campaign remains steadfast,” Dr. Sherif Amin added.

You Might Also Like

Japan’s Nikkei ends higher, gains capped amid continued concerns over global financial crisis

European Commission VP visits Egypt to discuss education, mobility, and migration issues

Developers have to offer innovative products, state should provide more facilities to stimulate industry: Kareem Mamoun

Tabarak Holding launches 4 exhibitions in Gulf region for Egyptian property export

Eight Developments, Gaballah Group sign contract with Mission 235 for Revolve Mall management

TAGGED: Novartis
Share this Article
Facebook Twitter Email Print
Previous Article Al-Sisi, Spanish PM discuss mutual cooperation, regional crises
Next Article 23.8% increase in Egypt-Spain trade exchange during 9M 2021
Ad image

Stay Connected

Facebook Like
Twitter Follow
Instagram Follow
Youtube Subscribe

Latest News

Germany has delivered Leopard 2 tanks to Ukraine: Scholz
Ukraine gets first batch of Leopard 2 tanks from Germany
Politics
China’s president Xi met with the King of Saudi Arabia Salman bin Abdulaziz Al-Saud in 2017. Reuters/Alamy
China’s latest diplomatic move will extend its trade, energy, financial and maritime power
Opinion Politics World
Saudi Arabia, to the surprise of many, chose China to broker its deal with Iran in March 2023. Chinese Foreign Ministry/Anadolu Agency via Getty Image
As longterm partnership with US fades, Saudi Arabia seeks to diversify its diplomacy – and recent deals with China, Iran and Russia fit this strategy
Opinion Politics
Japan's Nikkei ends higher, gains capped amid continued concerns over global financial crisis
Japan’s Nikkei ends higher, gains capped amid continued concerns over global financial crisis
Stock Market
//
Egypt’s only independent daily newspaper in English. Discuss the country’s latest with the paper’s reporters, editors, and other readers.

Quick Link

  • Home
  • Business
  • Politics
  • Interviews
  • Culture
  • Opinion
  • Sports
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

© 2023 DNE News. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?